Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Inventory (2018 - 2025)

UroGen Pharma's Change in Inventory history spans 7 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 397.43% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $7.2 million, up 103.63%, while the annual FY2025 figure was $7.2 million, 103.63% up from the prior year.
  • Change in Inventory reached $8.1 million in Q4 2025 per URGN's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $8.1 million in Q4 2025 to a low of -$1.6 million in Q1 2025.
  • Average Change in Inventory over 5 years is $768450.0, with a median of $293000.0 recorded in 2021.
  • Peak YoY movement for Change in Inventory: surged 1600.0% in 2023, then crashed 332.16% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $1.0 million in 2021, then crashed by 127.64% to -$283000.0 in 2022, then soared by 337.1% to $671000.0 in 2023, then skyrocketed by 143.37% to $1.6 million in 2024, then skyrocketed by 397.43% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Change in Inventory are $8.1 million (Q4 2025), $1.2 million (Q3 2025), and -$462000.0 (Q2 2025).